SCHEMBL30765459

SCHEMBL30765459

COC(=O)Cn1c(SC)ncc(NC(=O)c2ccc(-c3ccccc3)s2)c1=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 6/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
MAPT P10636 3/20 0.45
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
PPARG P37231 1/20 0.43
NCOA2 Q15596 1/20 0.43
NCOA1 Q15788 1/20 0.43
NCOA3 Q9Y6Q9 1/20 0.43
RXFP1 Q9HBX9 2/20 0.42
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
HPGD P15428 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
HDAC1 Q13547 2/20 0.40
MAPK11 Q15759 1/20 0.40
MAPK14 Q16539 1/20 0.40
WNT3A P56704 2/20 0.40
PRSS12 P56730 1/20 0.40
HDAC3 O15379 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30766096 0.76 RAB9A (0.45) TP53SMN1; SMN2MAPTNPC1RAB9A
SCHEMBL30765787 0.75 CASP1 (0.44) SMN1; SMN2RAB9AKDM4EALDH1A1
SCHEMBL30765956 0.75 CASP1 (0.41) TP53SMN1; SMN2MAPTRXFP1KDM4E
SCHEMBL31752304 0.69 ELANE (0.46) TP53MAPTHPGDPRSS12ESRRG
SCHEMBL30765704 0.68 KDM4E (0.43) TP53SMN1; SMN2MAPTNPC1RAB9A
SCHEMBL30765794 0.67 HDAC1 (0.46) SMN1; SMN2KDM4EALDH1A1HDAC1WNT3A
SCHEMBL8791232 0.67 NPC1 (0.61) TP53SMN1; SMN2MAPTNPC1RAB9A
SCHEMBL23460591 0.67 KDM4E (0.43) KDM4EALDH1A1
SCHEMBL30765683 0.67 TUBB4A (0.47) SMN1; SMN2KDM4EHDAC1WNT3AHDAC3
SCHEMBL30765492 0.67 ELANE (0.49) SMN1; SMN2KDM4EPTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed